Repealing or phasing out Medicaid expansion could reverse improvements in quality and service use and could be particularly harmful to low-income rural populations, said the authors of a study looking at the effect of Medicaid on community health centers.
Repealing or phasing out Medicaid expansion could reverse improvements in quality and service use and could be particularly harmful to low-income rural populations, said the authors of a study looking at the effect of Medicaid on community health centers (CHCs).
Patients in rural areas are predominantly low-income and disproportionately uninsured, noted the study, which was published in the June issue of Health Affairs.
Although there have been many positive effects noted from Medicaid expansion­—a recent literature review found that Medicaid expansion was associated with increases in coverage, service use, quality of care, and Medicaid spending—the effect on rural CHCs is unknown.
The researchers used nationally representative data to assess the 2-year impact of Medicaid expansion on insurance coverage and quality of care in CHCs. They also looked at the impact of expansion on the volume of CHC services for specific chronic conditions, such as asthma and diabetes, preventive visits, and mental health and substance abuse care.
Additionally, they looked at the different impacts of Medicaid expansion on CHCs in urban versus rural areas. The study compared all 578 CHCs in states that had expanded Medicaid by 2014 with a control group of all 431 CHCs in states that had not expanded Medicaid by 2014.
Using data for 2011 to 2015 on all CHCs, the study found that after 2 years, Medicaid expansion was associated with a decline of 11.44 percentage points in the share of CHC patients who were uninsured and an increase of 13.15 percentage points in those covered by Medicaid.
The 3 main outcomes were:
Rural CHCs in expansion states saw improvements in asthma treatment, BMI screening and follow-up, and hypertension control.
There were also increases in volumes for 18 of 21 types of visits—particularly those for mammograms, abnormal breast findings, alcohol-related disorders, and other substance abuse disorders.
Similar relative gains were not observed in urban CHCs in expansion states.
Repealing or phasing out Medicaid expansion could reverse these gains, the researchers noted. The study was released about a month after CMS released its strategy to improve rural healthcare.
However, some fear that one of the priorities of the Trump administration currently being carried out by CMS—imposing work requirements in order to get Medicare benefits—will fall the hardest on those in rural areas precisely because of some of the challenges that CMS is trying to address with its rural health strategy, such as a lack of transportation and providers
Reference
Cole MB, Wright B, Wilson IB, Galárraga O, Trivedi AN. Health Aff (Millwood). 2018;37(6):900-907. doi: 10.1377/hlthaff.2017.1542.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Understanding How Fitness Affects Digestive Diseases
April 18th 2025Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.
Read More
FDA Greenlights Dupilumab for Chronic Spontaneous Urticaria, Marking First Approval in a Decade
April 18th 2025Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives and itching remain uncontrolled by antihistamines.
Read More